S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:AXGN

AxoGen (AXGN) Stock Price, News & Analysis

$10.56
+0.23 (+2.23%)
(As of 02/29/2024 ET)
Today's Range
$10.47
$10.71
50-Day Range
$6.63
$10.67
52-Week Range
$3.45
$10.83
Volume
184,775 shs
Average Volume
471,533 shs
Market Capitalization
$454.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

AxoGen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
23.1% Upside
$13.00 Price Target
Short Interest
Healthy
3.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of AxoGen in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$93,750 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.58) to ($0.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

683rd out of 958 stocks

Electromedical Equipment Industry

14th out of 21 stocks


AXGN stock logo

About AxoGen Stock (NASDAQ:AXGN)

AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

AXGN Stock Price History

AXGN Stock News Headlines

AxoGen (NASDAQ:AXGN) Upgraded by StockNews.com to Buy
AxoGen (AXGN) to Release Quarterly Earnings on Tuesday
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
American Well Corporation (AMWL)
Axogen Stock (NASDAQ:AXGN), Short Interest Report
AxoGen (NASDAQ:AXGN) Downgraded by StockNews.com to Hold
AXGN Mar 2024 12.500 call
3 Best Stocks to Buy for Remarkable Earnings Acceleration
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Here's Why Momentum in AxoGen (AXGN) Should Keep going
AXGN Apr 2024 2.500 call
Axogen Says 2023 Revenue to Hit High End of Guidance
Axogen CEO Karen Zaderej to retire
See More Headlines
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
2/29/2024
Next Earnings (Confirmed)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:AXGN
Employees
394
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+23.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-28,950,000.00
Pretax Margin
-15.26%

Debt

Sales & Book Value

Annual Sales
$138.58 million
Book Value
$2.39 per share

Miscellaneous

Free Float
39,900,000
Market Cap
$453.65 million
Optionable
Optionable
Beta
1.07
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Karen  ZaderejMs. Karen Zaderej (Age 62)
    Chairman, President & CEO
    Comp: $852.18k
  • Mr. Michael Donovan (Age 59)
    Vice President of Operations
    Comp: $406.02k
  • Mr. Angelo G. Scopelianos Ph.D. (Age 68)
    Chief Research & Development Officer
    Comp: $540.91k
  • Mr. Nir Naor C.F.A. (Age 50)
    CPA, L.L.M., M.B.A., Chief Financial Officer
  • Ed Joyce
    Director of Investor Relations
  • Mr. Marc A. Began (Age 56)
    Executive VP, General Counsel & Chief Compliance Officer
  • Ms. Doris Quackenbush
    Vice President of Sales
  • Mr. Jens Schroeder Kemp
    Chief Marketing Officer
  • Mr. Erick DeVinney (Age 48)
    Chief Innovation Officer
  • Dr. Ivica Ducic M.D.
    Ph.D., Chief Medical Officer














AXGN Stock Analysis - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price target for 2024?

4 Wall Street analysts have issued 1 year price targets for AxoGen's stock. Their AXGN share price targets range from $9.00 to $20.00. On average, they predict the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 23.1% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2024?

AxoGen's stock was trading at $6.83 at the beginning of 2024. Since then, AXGN stock has increased by 54.6% and is now trading at $10.56.
View the best growth stocks for 2024 here
.

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our AXGN earnings forecast
.

How can I listen to AxoGen's earnings call?

AxoGen will be holding an earnings conference call on Tuesday, March 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 877-407-0993.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The medical equipment provider had revenue of $31.20 million for the quarter, compared to the consensus estimate of $34.65 million. AxoGen had a negative net margin of 15.26% and a negative trailing twelve-month return on equity of 23.44%. During the same period in the prior year, the company posted ($0.04) earnings per share.

What ETF holds AxoGen's stock ?

iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its fourth quarter 2023 earnings guidance on Thursday, January, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $42.7 million-$42.7 million, compared to the consensus revenue estimate of $40.7 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

Who are AxoGen's major shareholders?

AxoGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.73%), Perceptive Advisors LLC (1.88%), Dimensional Fund Advisors LP (1.35%), Goldman Sachs Group Inc. (1.18%), Northern Trust Corp (0.89%) and Nuveen Asset Management LLC (0.82%). Insiders that own company stock include Amy Mcbride Wendell, Gregory Gene Freitag, Guido J Neels, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXGN) was last updated on 2/29/2024 by MarketBeat.com Staff